Ludwig Maximilian University

SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.

Janus kinase inhibitors have delivered on some, but not all, of the promises that were expected of them upon approval in 2012, a speaker said at EULAR 2022 Congress.

Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are more likely to develop severe infections after chimeric antigen receptor T-cell therapy.